Health plan paid cost of epilepsy in 2009 in the U.S.

Wilner, Andrew N.; Sharma, Bal Krishan; Soucy, Alison; Krueger, Andrew

doi:10.1016/j.yebeh.2012.08.029

Cited by 15 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirteen studies identified cases based on AED use (studies 3–12, 15, 16, and 18) . Eight studies included both active and inactive epilepsy cases (1, 2, 13, 14, 17, and 21–23) …”

Section: Resultsmentioning

confidence: 99%

“…All selected studies except two (studies 19 and 20, which calculated costs only for hospitalizations) estimated direct costs for a comprehensive set of services that included inpatient hospitalizations, outpatient visits and procedures, and medications over a fixed time period (in most cases, 1 year). Of the 22 studies estimating comprehensive direct costs, 10 (studies 2, 4–6, 8, 9, 13, 14, 18, and 21), also reported cost estimates for each cost component, although the components varied across studies …”

Section: Resultsmentioning

confidence: 99%

“…Among the studies estimating epilepsy‐specific costs, a key difference was whether the estimates were based on using a comparative versus bottom‐up method for attribution. Seven studies used the comparative method (studies number 3, 10, 13, 14, 17, 21, and 23), in which epilepsy‐specific costs represent the difference between total direct costs for people with epilepsy and people without epilepsy . These studies usually employed multivariate regression analysis to control for other sociodemographic differences in the epilepsy and nonepilepsy populations.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The direct cost of epilepsy in the United States: A systematic review of estimates

Begley¹,

Durgin²

2015

Epilepsia

220

136

View full text Add to dashboard Cite

SUMMARYObjective: To develop estimates of the direct cost of epilepsy in the United States for the general epilepsy population and sub-populations by systematically comparing similarities and differences in types of estimates and estimation methods from recently published studies. Methods: Papers published since 1995 were identified by systematic literature search. Information on types of estimates, study designs, data sources, types of epilepsy, and estimation methods was extracted from each study. Annual per person cost estimates from methodologically similar studies were identified, converted to 2013 U.S. dollars, and compared. Results: From 4,104 publications discovered in the literature search, 21 were selected for review. Three were added that were published after the search. Eighteen were identified that reported estimates of average annual direct costs for the general epilepsy population in the United States. For general epilepsy populations (comprising all clinically defined subgroups), total direct healthcare costs per person ranged from $10,192 to $47,862 and epilepsy-specific costs ranged from $1,022 to $19,749. Four recent studies using claims data from large general populations yielded relatively similar epilepsy-specific annual cost estimates ranging from $8,412 to $11,354. Although more difficult to compare, studies examining direct cost differences for epilepsy sub-populations indicated a consistent pattern of markedly higher costs for those with uncontrolled or refractory epilepsy, and for those with comorbidities. Significance: This systematic review found that various approaches have been used to estimate the direct costs of epilepsy in the United States. However, recent studies using large claims databases and similar methods allow estimation of the direct cost burden of epilepsy for the general disease population, and show that it is greater for some patient subgroups. Additional research is needed to further understand the broader economic burden of epilepsy and how it varies across subpopulations.

show abstract

“…Thirteen studies identified cases based on AED use (studies 3–12, 15, 16, and 18) . Eight studies included both active and inactive epilepsy cases (1, 2, 13, 14, 17, and 21–23) …”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The direct cost of epilepsy in the United States: A systematic review of estimates

Begley¹,

Durgin²

2015

Epilepsia

220

136

View full text Add to dashboard Cite

show abstract

“…Newer drugs may be more expensive compared with older drugs, but if they reduce epilepsy-related hospital encounters, they may also be cost-effective [8,10,[14][15][16]. Even if they are no more efficacious in suppressing seizures, if they lead to better patient adherence to therapy by indirect routes such as better tolerability or fewer daily doses, they can reduce morbidity [7] and, thus, expense [17].…”

Section: Discussionmentioning

confidence: 99%

Newer antiepileptic drug use and other factors decreasing hospital encounters

Faught

Helmers

Begley

et al. 2015

Epilepsy & Behavior

View full text Add to dashboard Cite

“…Several studies had investigated the economic burden of epilepsy in different geographical regions (Hong et al, 2009;Thomas et al, 2001;Wilner et al, 2012), the estimated costs related to epilepsy being as high as D 15.5 billion/year in Europe only (Pugliatti et al, 2007). The cost impending on the side effects of antiepileptic treatments probably Table 1 Epilepsy terminology.…”

Section: Introductionmentioning

confidence: 99%